Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00 at HC Wainwright

Posted by Brenda Bartman on Aug 11th, 2026

Hemab Therapeutics (NASDAQ:COAG – Get Free Report) had its price target upped by equities researchers at HC Wainwright from $52.00 to $60.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 16.91% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Jefferies Financial Group upped their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. The Goldman Sachs Group started coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target for the company. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Finally, Wedbush restated an “outperform” rating and set a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a research report on Monday, July 13th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Hemab Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.60.

Read Our Latest Report on COAG

Hemab Therapeutics Stock Performance

COAG traded up $1.45 during trading on Tuesday, hitting $51.32. The company’s stock had a trading volume of 57,573 shares, compared to its average volume of 320,959. Hemab Therapeutics has a one year low of $23.00 and a one year high of $53.61. The stock has a market cap of $2.40 billion and a price-to-earnings ratio of -2.14. The stock has a 50 day moving average price of $36.98.

Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). Analysts expect that Hemab Therapeutics will post -2.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of Hemab Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The stock was bought at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the purchase, the insider directly owned 6,444,637 shares of the company’s stock, valued at approximately $160,987,032.26. This represents a 0.96% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have bought 72,467 shares of company stock worth $1,809,595.

About Hemab Therapeutics

(Get Free Report)

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.